-
Nov 18, 2024 | 
cancertodaymag.org | Sandra Gordon
NEW RESEARCH SHEDS LIGHT on an apparent contradiction in prostate cancer treatment: that controlling cancer growth can be achieved both by lowering hormone levels and, in some cases, by raising them. Men in the early stages of prostate cancer typically undergo androgen deprivation therapy (ADT), which uses prescription medication to lower the levels of androgens, male hormones including testosterone, or block their action in prostate cells, stopping them from fueling cancer cell growth.
-
Oct 7, 2024 | 
cancertodaymag.org | Sandra Gordon
MAMMOGRAPHY CONTINUES to be the tool most widely used for breast cancer screening and detection. But it isn’t foolproof. Dense breast tissue, which consists of fibrous and glandular tissue, appears similar to cancer on a mammogram and can make it harder for radiologists to distinguish cancer and breast tissue. Most states already require some kind of breast density assessment in the summary given to patients about their mammogram results.
-
Aug 12, 2024 | 
cancertodaymag.org | Sandra Gordon
SENSORIMOTOR TRAINING, an exercise program designed to stimulate the nervous system and improve motor control, reduced the risk of chemotherapy-induced peripheral neuropathy, a type of nerve damage caused by some types of chemotherapy in a study of cancer patients published in the July 2024 issue of JAMA Internal Medicine.
-
May 29, 2024 | 
cancertodaymag.org | Sandra Gordon
Regularly taking low-dose aspirin as recommended by a doctor has proven to be an effective way to reduce the risk of having another stroke or heart attack. But it may also protect against colorectal cancer, according to an Italian study published online April 22 in Cancer.
-
Apr 9, 2024 | 
cancertodaymag.org | Kevin McLaughlin |Eric Fitzsimmons |Laura Gesualdi-Gilmore |Sandra Gordon
PROGRESS IN EARLY DETECTION and treatment of cancer means more people are living longer after a diagnosis, leading some researchers to focus on measuring and improving quality of life (QOL) for patients and survivors.
-
Apr 8, 2024 | 
cancertodaymag.org | Eric Fitzsimmons |Laura Gesualdi-Gilmore |Sandra Gordon |Taneia Surles
THE FOOD AND DRUG ADMINISTRATION’S (FDA) Accelerated Approval Program uses early indications of response to help promising new treatments reach patients sooner, but a study found some cancer drugs that receive this designation are being granted regular approval without showing a benefit in survival or quality of life.
-
Apr 5, 2024 | 
cancertodaymag.org | Laura Gesualdi-Gilmore |Sandra Gordon |Taneia Surles |Suzanne McBride
Every week, the editors of Cancer Today magazine bring you the top news for cancer patients from around the internet. Stay up to date with the latest in cancer research and care by subscribing to our e-newsletter. More people with cancer are taking part in clinical trials, according to a study published online April 2 in the Journal of Clinical Oncology.
-
Apr 2, 2024 | 
brnw.ch | Laura Gesualdi-Gilmore |Sandra Gordon |Taneia Surles |Suzanne McBride
A NEW GUIDELINE released by the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) recommends that all women diagnosed with breast cancer who are 65 years old or younger should be offered germline genetic testing for BRCA1 and BRCA2 mutations.
-
Apr 2, 2024 | 
cancertodaymag.org | Laura Gesualdi-Gilmore |Sandra Gordon |Taneia Surles |Suzanne McBride
A NEW GUIDELINE released by the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) recommends that all women diagnosed with breast cancer who are 65 years old or younger should be offered germline genetic testing for BRCA1 and BRCA2 mutations.
-
Mar 29, 2024 | 
cancertodaymag.org | Sandra Gordon |Taneia Surles |Suzanne McBride |Kyle Bagenstose
Every week, the editors of Cancer Today magazine bring you the top news for cancer patients from around the internet. Stay up to date with the latest in cancer research and care by subscribing to our e-newsletter. Older patients with acute myeloid leukemia (AML) who received an allogenic stem cell transplant have shown improved survival rates over the past two decades, according to a study published online March 22 in Clinical Cancer Research.
